Invenra’s INV724 Gets FDA Rare Pediatric Disease and Orphan Drug Designations for Neuroblastoma
Invenra Inc. is excited to announce that its cutting-edge bispecific antibody, INV724, designed for neuroblastoma treatment, has received both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations from the…
ADVI Health Partners with Health Analytic Research for Acquisition
ADVI Health is excited to announce its acquisition of Partnership for Health Analytic Research (PHAR), a leading consultancy specializing in global health technology assessment (HTA) and health economics and outcomes…
Maria’s Journey: Navigating Life with a Rare Liver Disease
In 2017, Maria Morais began experiencing severe abdominal pain, which led to gall bladder surgery. However, when the procedure failed to alleviate her discomfort, follow-up tests revealed alarmingly high liver…
Aetna Contributes $100,000 to Support Safer Foundation
Aetna Better Health® of Illinois, a CVS Health® company (NYSE: CVS), has announced a generous community investment of $100,000 to the Safer Foundation. This funding aims to assist in housing…
GSK’s B7-H3 Antibody-Drug Conjugate Receives FDA Breakthrough Designation for Small-Cell Lung Cancer
GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to GSK5764227 (GSK’227), an investigational B7-H3-targeted antibody-drug conjugate (ADC) being studied…
Leqembi (lecanemab) Approved for Early Alzheimer’s Disease Treatment in Great Britain
Eisai Co., Ltd. (Tokyo, CEO: Haruo Naito) and Biogen Inc. (Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain…
European Commission Grants Approval to Moderna’s RSV Vaccine, mRESVIA
Moderna, Inc. (NASDAQ) has announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA vaccine designed to protect adults aged 60 and older from lower…
Pfizer and BioNTech Get U.S. FDA Approval for Omicron KP.2-Adapted COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for their COMIRNATY® COVID-19…
China Approves PADCEV™ for Advanced Urothelial Cancer
Astellas Pharma Inc. (TSE: 4503), led by President and CEO Naoki Okamura, has announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted…
TEPKINLY® (epcoritamab) Gets Second European Approval for Relapsed/Refractory Follicular Lymphoma
Genmab A/S (Nasdaq: GMAB) has announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for adult patients with relapsed or refractory (R/R)…
BioMarin Appoints New Leaders in R&D and Business Development
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has announced key leadership changes in its research and development and business development teams. Effective September 30, Greg Friberg, M.D., will join the company as…
WuXi Biologics Announces Strong Interim Results for 2024
WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) providing comprehensive solutions for biologics discovery, development, and…